Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

ResMed Yönetim

Yönetim kriter kontrolleri 4/4

ResMed's CEO'su Mick Farrell, Mar2013 tarihinde atandı, in görev süresi 11.58 yıldır. in toplam yıllık tazminatı $ 13.87M olup, şirket hissesi ve opsiyonları dahil olmak üzere 8.1% maaş ve 91.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.32% ine doğrudan sahiptir ve bu hisseler $ 114.31M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.7 yıl ve 8.9 yıldır.

Anahtar bilgiler

Mick Farrell

İcra Kurulu Başkanı

US$13.9m

Toplam tazminat

CEO maaş yüzdesi8.1%
CEO görev süresi11.6yrs
CEO sahipliği0.3%
Yönetim ortalama görev süresi2.7yrs
Yönetim Kurulu ortalama görev süresi8.9yrs

Son yönetim güncellemeleri

Recent updates

Why ResMed's Rally Is Just Getting Started

Sep 18

ResMed Inc.'s (NYSE:RMD) Earnings Haven't Escaped The Attention Of Investors

Sep 13
ResMed Inc.'s (NYSE:RMD) Earnings Haven't Escaped The Attention Of Investors

ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53

Aug 05
ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53

Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?

Jul 29
Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?

Returns On Capital Are A Standout For ResMed (NYSE:RMD)

Jul 15
Returns On Capital Are A Standout For ResMed (NYSE:RMD)

ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating

Jul 03

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued

Jul 02
An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued

ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Apr 30
ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Apr 30
Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

Apr 18
ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Mar 22
With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

Mar 10
Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Feb 12
An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Why ResMed Is One Of My Top Picks In 2024

Jan 22

A First Look At ResMed

Jan 09

ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

Dec 20
ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital

Dec 06
Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital

Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Nov 10
Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?

Nov 01
Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?

ResMed: Weight-Loss Drug Worries Provide Buying Opportunity

Oct 28

ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity

Sep 12

ResMed Has Become A Steal (Rating Upgrade)

Aug 10

ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year

Aug 07
ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year

ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger

Jul 30
ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger

Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Jul 16
Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Compound Your Wealth With ResMed

Jul 04

A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)

Jul 02
A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)

We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt

May 26
We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt

ResMed (NYSE:RMD) Could Be Struggling To Allocate Capital

Apr 24
ResMed (NYSE:RMD) Could Be Struggling To Allocate Capital

Here's Why ResMed (NYSE:RMD) Has Caught The Eye Of Investors

Apr 09
Here's Why ResMed (NYSE:RMD) Has Caught The Eye Of Investors

A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD)

Mar 26
A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD)

CEO Tazminat Analizi

Mick Farrell'un ücretlendirmesi ResMed'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

US$1b

Mar 31 2024n/an/a

US$958m

Dec 31 2023n/an/a

US$890m

Sep 30 2023n/an/a

US$907m

Jun 30 2023US$14mUS$1m

US$898m

Mar 31 2023n/an/a

US$863m

Dec 31 2022n/an/a

US$809m

Sep 30 2022n/an/a

US$786m

Jun 30 2022US$12mUS$1m

US$779m

Mar 31 2022n/an/a

US$779m

Dec 31 2021n/an/a

US$522m

Sep 30 2021n/an/a

US$500m

Jun 30 2021US$10mUS$1m

US$475m

Mar 31 2021n/an/a

US$457m

Dec 31 2020n/an/a

US$699m

Sep 30 2020n/an/a

US$680m

Jun 30 2020US$10mUS$1m

US$622m

Mar 31 2020n/an/a

US$513m

Dec 31 2019n/an/a

US$455m

Sep 30 2019n/an/a

US$419m

Jun 30 2019US$10mUS$967k

US$405m

Mar 31 2019n/an/a

US$446m

Dec 31 2018n/an/a

US$450m

Sep 30 2018n/an/a

US$335m

Jun 30 2018US$9mUS$934k

US$316m

Tazminat ve Piyasa: Mick 'ın toplam tazminatı ($USD 13.87M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 13.04M ).

Tazminat ve Kazançlar: Mick 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.


CEO

Mick Farrell (52 yo)

11.6yrs

Görev süresi

US$13,868,641

Tazminat

Mr. Michael J. Farrell, also known as Mick, BE, SM, MBA, served as Director of Fullbay, Inc. since May 2023 until 2023. He serves as Member of Advisory Board at Green Sun Medical, LLC. He serves as the Chi...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Michael Farrell
CEO & Chairman11.6yrsUS$13.87m0.32%
$ 109.4m
Peter Farrell
Founderno dataUS$680.27k0.057%
$ 19.5m
Brett Sandercock
Chief Financial Officer18.8yrsUS$3.11m0.066%
$ 22.6m
Robert Douglas
Special Advisorless than a yearUS$6.67m0.18%
$ 61.8m
Kaushik Ghoshal
Chief Commercial Officer - SaaS2.7yrsUS$3.31m0.015%
$ 5.1m
Alastair Robertson
Chief Information Officerless than a yearVeri yokVeri yok
Amy Wakeham
Chief Investor Relations Officer1.5yrsVeri yokVeri yok
Michael Rider
Chief Legal Officer1.3yrsVeri yok0.0072%
$ 2.5m
Jim Ellis
Chief Compliance Officer6.8yrsVeri yokVeri yok
Yvonne-Katrin Pucknat
Chief Marketing Officerless than a yearVeri yokVeri yok
Vered Keisar
Chief People Officer3.6yrsVeri yokVeri yok
Hemanth Reddy
Chief Strategy Officer9.8yrsVeri yokVeri yok

2.7yrs

Ortalama Görev Süresi

60.5yo

Ortalama Yaş

Deneyimli Yönetim: RMD 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.7 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Michael Farrell
CEO & Chairman11.6yrsUS$13.87m0.32%
$ 109.4m
Peter Farrell
Founder35.3yrsUS$680.27k0.057%
$ 19.5m
Richard Sulpizio
Independent Director19.2yrsUS$340.06k0.010%
$ 3.5m
Ronald Taylor
Lead Independent Director19.8yrsUS$372.56k0.014%
$ 4.9m
Jan De Witte
Independent Non-Executive Director5.4yrsUS$320.06k0.0039%
$ 1.3m
Harjit Gill
Independent Director5.9yrsUS$320.06k0.0049%
$ 1.7m
Carol Burt
Independent Director10.9yrsUS$360.06k0.010%
$ 3.5m
Karen Drexler
Independent Director6.9yrsUS$320.06k0.0052%
$ 1.8m
Desney Tan
Independent Director2.9yrsUS$320.06k0.0014%
$ 484.2k
John Hernandez
Independent Director2.9yrsUS$320.06k0.0014%
$ 484.2k

8.9yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: RMD 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.9 yıldır).